Keya Medical US celebrates the achievements of the team in China and their commitment to the commercialization of our deep-learning solution for noninvasive CT FFR assessment, DEEPVESSEL FFR.
In 2022, Keya Medical China participated in numerous domestic cardiovascular conferences, which brought together domestic and foreign specialists in cardiology, radiology, and the application of AI in healthcare management. The development and implementation of advanced imaging technologies for cardiovascular assessment became a focal point of expert panel discussions and sessions.
Since obtaining NMPA certification in January 2020, DEEPVESSEL FFR has been deployed in more than 1,100 hospitals across the country, covering 30 million patients. With its exploration and innovation in the field of medical AI, Keya Medical ranked 7th in the “2022 Future Medical Top 100 · China’s Top 100 Innovative Medical Devices List”. Keya Medical ranked 1st in the field of medical AI.
Keya Medical participated as a strategic partner at the 10th Annual SCCT China IRC Conference. The forum brought together cardiology and radiology experts, and leaders of major cardiovascular imaging societies in Europe, America, and Asia, to discuss new research topics and technologies, big data, and artificial intelligence in cardiology. One of the hot topics was the new era of functional imaging. In a panel discussion with Keya Medical, Dr. Bin Lu, Professor and Director of the Department of Radiologic Imaging, Fuwai Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing., added CT FFR to the Top 10 cardiology events of the decade.
The conference is an international exchange platform dedicated to the latest academic trends and innovative achievements in cardiology. The focus of the cardiovascular imaging forum was the latest clinical application development and advantages of cutting-edge imaging technologies. Speakers from leading medical centers in China discussed the status, research progress, and clinical cases of CT-FFR in guidance for revascularization. Li Guang, Director, Algorithm Research Development at Keya Medical, discussed the differences between CT FFR based on Deep Learning and Computational Fluid Dynamics models. Dr. Mariusz Kruk, an investigator of Keya Medical’s ADAPT study, presented “Research progress of CT FFR based on deep learning (AI).” Dr. Kruk introduced compelling clinical data about the diagnostic performance of deep learning-based CT FFR and CCTA + CT FFR as a front-line pathway in diagnosing patients with chest pain.
As a leading enterprise in the AI in medical imaging track, Keya Medical participated in releasing the “2022 China Artificial Intelligence Medical Imaging Industry Research Report” at the 2022 World Artificial Intelligence Conference (WAIC) in Shanghai. At the “AI Medical and Metaverse Forum,” EqualOcean released the report based on more than 6,000 surveys and 30 enterprise interviews, and industry data.
The 19th Conference on Cardiac Imaging and Cardiac Intervention (2022CICI) and the 2022 China Cardiovascular Disease Forum covered coronary disease diagnosis, treatment, and the application of advanced imaging technologies. An essential part of the conference was the “Noninvasive Coronary Fractional Flow Reserve (CT FFR) Symposium,” co-organized by Keya Medical.
Based on the technical expertise and years of exploration in the AI medical industry, Keya Medical is building its ecosystem of comprehensive solutions for health management. At the GE Healthcare Boao Health Leaders Summit, also held in July, Keya Medical leadership and other industry leaders discussed the role of AI in the early prevention and precise management of cardiovascular and cerebrovascular diseases. The forum serves as a comprehensive and authoritative platform for high-level dialogue and practical cooperation, focusing specifically on innovation, cross-border integration trends, and the collaboration of governments, businesses, and higher education institutions with the health industry.
During the online conference, Keya Medical co-organized the Calculation of Fractional Flow Reserve with CT (FFR-CT) Forum and Noninvasive Coronary Fractional Flow Reserve (CT FFR) Forum. The forum revolved around the interpretation of the 2021 AHA/ACC chest pain assessment and diagnosis guidelines on the application of CT FFR technology. It discussed the research progress and application of CT FFR in recent years.
Keya Medical is an international medical technology company developing deep learning-based medical devices for disease diagnosis and treatment. The company is committed to creating solutions that deliver clinical value at all stages in the patient care process, covering specialties including cardiology, neurology, pulmonology, pathology, and surgery. Keya Medical has four centers of excellence in Beijing, Shanghai, Shenzhen, and Seattle. To learn more about Keya Medical, follow us on LinkedIn, Twitter, and Facebook.
 Gulati, et al. 2021 AHA/ACC/ASE/CHES/SAEM/SCCT/SCMR Guideline for the Evaluation & Diagnosis of Chest Pain. Circulation.